Jérémy Lambert

2.8k total citations
69 papers, 2.1k citations indexed

About

Jérémy Lambert is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Jérémy Lambert has authored 69 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Molecular Biology and 13 papers in Hematology. Recurrent topics in Jérémy Lambert's work include Psoriasis: Treatment and Pathogenesis (10 papers), Spondyloarthritis Studies and Treatments (7 papers) and Polyomavirus and related diseases (7 papers). Jérémy Lambert is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (10 papers), Spondyloarthritis Studies and Treatments (7 papers) and Polyomavirus and related diseases (7 papers). Jérémy Lambert collaborates with scholars based in United States, France and United Kingdom. Jérémy Lambert's co-authors include Vladimir J.N. Bykov, Klas G. Wiman, Pierre Hainaut, Stephen F. Kingsmore, Barry Schweitzer, Shawn O’Malley, Jan Bergman, Zhengrong Zhu, David C. Ward and Steven Wiltshire and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Jérémy Lambert

61 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jérémy Lambert United States	20	1.3k	621	326	279	182	69	2.1k
Vicky Robinson United Kingdom	17	563 0.4×	385 0.6×	178 0.5×	179 0.6×	265 1.5×	35	1.8k
Hongyan Xu United States	21	678 0.5×	229 0.4×	161 0.5×	247 0.9×	144 0.8×	93	1.6k
Dongsheng Xiong China	28	952 0.7×	602 1.0×	117 0.4×	234 0.8×	311 1.7×	106	1.9k
James M. Reuben United States	22	616 0.5×	585 0.9×	236 0.7×	137 0.5×	137 0.8×	47	2.2k
Martin Trepel Germany	36	2.3k 1.8×	994 1.6×	145 0.4×	724 2.6×	257 1.4×	108	4.2k
Jane Azizkhan‐Clifford United States	20	2.0k 1.5×	362 0.6×	134 0.4×	533 1.9×	419 2.3×	37	2.9k
J. Thomas Parsons United States	31	1.0k 0.8×	556 0.9×	181 0.6×	128 0.5×	325 1.8×	58	3.1k
Hiroko Endo Japan	24	827 0.6×	791 1.3×	335 1.0×	96 0.3×	446 2.5×	81	2.0k
Carsten Grötzinger Germany	25	971 0.8×	818 1.3×	368 1.1×	304 1.1×	336 1.8×	63	2.5k
Hagit Dafni Israel	23	835 0.6×	200 0.3×	261 0.8×	571 2.0×	273 1.5×	35	2.1k

Countries citing papers authored by Jérémy Lambert

Since Specialization

Citations

This map shows the geographic impact of Jérémy Lambert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérémy Lambert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérémy Lambert more than expected).

Fields of papers citing papers by Jérémy Lambert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérémy Lambert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérémy Lambert. The network helps show where Jérémy Lambert may publish in the future.

Co-authorship network of co-authors of Jérémy Lambert

This figure shows the co-authorship network connecting the top 25 collaborators of Jérémy Lambert. A scholar is included among the top collaborators of Jérémy Lambert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérémy Lambert. Jérémy Lambert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Langley, Richard G., Mark Lebwohl, Bruce Strober, et al.. (2025). Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. Journal of the American Academy of Dermatology. 93(3). 644–653. 1 indexed citations

Warren, Richard B., Mark Lebwohl, Diamant Thaçi, et al.. (2025). Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. British Journal of Dermatology. 193(1). 44–55. 3 indexed citations

Gladman, Dafna, Philip J. Mease, Laure Gossec, et al.. (2025). Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies. The Journal of Rheumatology. 52(5). 466–478.

Orenstein, Lauren A.V., Vivian Y. Shi, Hadar Lev‐Tov, et al.. (2024). Bimekizumab Impact on Pain in Moderate to Severe Hidradenitis Suppurativa: Week 16 Results from BE HEARD I & II. SKIN The Journal of Cutaneous Medicine. 8(1). s350–s350. 2 indexed citations

Holekamp, Nancy M., Brittany Gentile, Audrey Giocanti‐Auregan, et al.. (2024). Patient Experience Survey Of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Ophthalmic Research. 67(1). 311–321. 6 indexed citations

Tillett, William, Peter Nash, Laura C. Coates, et al.. (2024). Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies. Therapeutic Advances in Musculoskeletal Disease. 16. 1759720X241288071–1759720X241288071.

Gossec, Laure, Ana‐Maria Orbai, Laura C. Coates, et al.. (2024). Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis. RMD Open. 10(1). e003548–e003548. 1 indexed citations

Augustin, Matthias, Alice B. Gottlieb, Mark Lebwohl, et al.. (2024). Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis. Dermatology and Therapy. 14(10). 2841–2857. 6 indexed citations

Kokolakis, Georgios, Mark Lebwohl, Peter Foley, et al.. (2024). AB0490 BIMEKIZUMAB EFFICACY THROUGH 3 YEARS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: LONG-TERM POOLED ANALYSIS FROM BE BRIGHT. Annals of the Rheumatic Diseases. 83. 1513–1513.

10.

Meadows, Keith, Brian Calimlim, Sandra Goss, et al.. (2023). A Patient-Centred Conceptual Model of Nocturnal Scratch and its Impact in Atopic Dermatitis: A Mixed-Methods Study Supporting the Development of Novel Digital Measurements. SHILAP Revista de lepidopterología. 3(5). 4 indexed citations

11.

Giocanti‐Auregan, Audrey, Alfredo García‐Layana, Tünde Pető, et al.. (2022). Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study. SHILAP Revista de lepidopterología. 30 indexed citations

12.

Turner‐Stokes, Lynne, Klemens Fheodoroff, Jorge Jacinto, et al.. (2021). The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: A first psychometric evaluation. Journal of Rehabilitation Medicine. 54. jrm00243–jrm00243. 1 indexed citations

13.

Turner‐Stokes, Lynne, Klemens Fheodoroff, Jorge Jacinto, et al.. (2021). The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: Development and responsiveness. Journal of Rehabilitation Medicine. 54. jrm00244–jrm00244. 3 indexed citations

14.

Eriksson, Jennifer, et al.. (2020). Experience of mismatch repair/microsatellite instability (MMR/MSI) testing among patients with advanced/metastatic colorectal cancer in the US. Current Medical Research and Opinion. 36(8). 1355–1361. 4 indexed citations

15.

Strober, Bruce, Alan Menter, C. Leonardi, et al.. (2020). Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies. Journal of the European Academy of Dermatology and Venereology. 34(12). 2830–2838. 41 indexed citations

16.

Carroll, Liz, et al.. (2019). Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom. SHILAP Revista de lepidopterología. 12 indexed citations

17.

Eriksson, Jennifer, et al.. (2019). Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer. Journal of Clinical Medicine. 8(4). 558–558. 19 indexed citations

18.

Lambert, Thierry, et al.. (2018). PSY223 - QUALITATIVE RESEARCH IN HAEMOPHILIA A: EMICIZUMAB TRANSFORMS LIFESTYLE OF PATIENTS WITH INHIBITOR. Value in Health. 21. S474–S474. 1 indexed citations

19.

Lambert, Jérémy, Ali Moshfegh, Pierre Hainaut, Klas G. Wiman, & Vladimir J.N. Bykov. (2009). Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 29(9). 1329–1338. 85 indexed citations

20.

Lambert, Jérémy, Dmitry B. Veprintsev, Dan Segerbäck, et al.. (2009). PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain. Cancer Cell. 15(5). 376–388. 450 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact